resveratrol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on flow-mediated dilation
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“Fasting FMD values at the end of the placebo and trans-resveratrol periods were not significantly different.”
Quoted verbatim from Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants.. - Study
- crossover
- Duration
- 4 weeks
- Dose
- trans-resveratrol 2 x 75 mg/day vs placebo (cellulose)
- Population
- Overweight and slightly obese healthy adults aged 45-70 years; fasting measurement at the end of each 4-week period
Trans-Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants.2017PMID:28604618Industry fundedPermalink
Keep reading
- Everything the graph holds on resveratrol
- Every compound studied against Flow-mediated dilation
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M5S93RE4EZ870HH6W6FH3VSC